Axsome Acquires Exclusive Global Rights to Takeda's TAK-063
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Should l Buy AXSM?
Axsome Therapeutics (AXSM) announced that it has entered into an asset purchase agreement to obtain exclusive global rights to TAK-063, an oral, potent, and selective phosphodiesterase 10A inhibitor from Takeda (TAK). Axsome intends to develop the selective inhibitor for the treatment of schizophrenia and Tourette syndrome, and plans to begin Phase 3 trial-enabling activities for the schizophrenia indication in 2026. Balipodect has completed a 164-patient proof-of-concept Phase 2 trial in schizophrenia. The selective PDE10A inhibitor has demonstrated a favorable safety and tolerability profile in clinical studies in over 360 individuals to date. Under the terms of the agreement, Axsome obtained worldwide commercial, development, and manufacturing rights to balipodect. Takeda received an upfront payment and is eligible to receive additional payments related to development, regulatory, and commercial milestones for the first two indications, as well as royalties related to potential global net sales.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AXSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AXSM
Wall Street analysts forecast AXSM stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 169.020
Low
153.00
Averages
209.54
High
260.00
Current: 169.020
Low
153.00
Averages
209.54
High
260.00
About AXSM
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Axsome Acquires Global Rights to TAK-063 from Takeda
- Asset Purchase Agreement: Axsome Therapeutics has signed an asset purchase agreement with Takeda Pharmaceutical to acquire exclusive global rights to TAK-063 (balipodect), further expanding its leading CNS portfolio and demonstrating strategic positioning in neuropsychiatric treatment.
- Clinical Trial Plans: Axsome intends to initiate Phase 3 trial-enabling activities for schizophrenia in 2026, indicating strong confidence in the development of balipodect and aiming to improve treatment outcomes for patients through this novel mechanism.
- Clinical Trial Results: Balipodect has shown positive results in a 164-patient proof-of-concept Phase 2 trial for schizophrenia and has demonstrated a favorable safety and tolerability profile in clinical studies involving over 360 individuals, enhancing its market potential.
- Financial Arrangement: Under the agreement, Axsome obtains worldwide commercial, development, and manufacturing rights to balipodect, while Takeda receives an upfront payment and is eligible for additional payments related to development, regulatory, and commercial milestones, as well as royalties on potential global net sales, ensuring mutual benefit.
See More
FDA Accelerates Biosimilar Drug Development and Approves New Treatments
- Accelerated Biosimilar Development: On March 9, 2026, the FDA recommended streamlining unnecessary clinical pharmacokinetic studies when scientifically justified, aiming to expedite biosimilar drug development and improve medicine affordability, thereby enhancing market competitiveness.
- Alternative to Animal Testing: The FDA released draft guidance on March 18, 2026, to assist drug developers in validating new approach methodologies as alternatives to animal testing, reflecting its commitment to scientific rigor and humane practices, which could reshape drug development standards.
- New Therapy Approval: On March 10, 2026, the FDA approved Wellcovorin as the first treatment for cerebral folate deficiency, a rare neurological condition, marking a significant advancement in neuroscience and potentially offering new hope for patients.
- Gene Therapy Innovation: The FDA approved Rocket Pharma's Kresladi on March 26, 2026, as the first gene therapy for Severe Leukocyte Adhesion Deficiency Type I, showcasing the potential of gene therapy in treating rare diseases and possibly driving stock price increases for related biotech companies.
See More
Summit Therapeutics Faces FDA Review Risk for Ivonescimab
- Regulatory Application Progress: Summit Therapeutics has filed for FDA approval of ivonescimab, which is already approved in China; however, survival data from Western countries has not shown statistical significance, potentially jeopardizing its marketing authorization.
- Market Valuation Changes: Currently, Summit's market cap stands at $12 billion, approximately 48% higher than Axsome and 17% higher than Madrigal, but if the FDA declines ivonescimab, the stock could face a drop of over 20%.
- Competitor Dynamics: Axsome Therapeutics and Madrigal Pharmaceuticals reported revenue growth of 65.5% and 432% in 2025, respectively, indicating strong market potential that could see them surpass Summit in the near future.
- Investor Risk Assessment: While Summit has long-term potential in oncology, its short-term outlook is uncertain, prompting investors to carefully evaluate risks, especially in light of possible negative clinical trial outcomes.
See More
Summit Therapeutics Faces FDA Approval Risk for Ivonescimab
- FDA Approval Crucial: Summit Therapeutics has filed for FDA approval of ivonescimab, which is already approved in China; however, the drug has not shown statistically significant overall survival in Western countries, and a rejection could lead to a significant drop in stock price.
- Intensifying Market Competition: Axsome Therapeutics and Madrigal Pharmaceuticals have market caps of $8.1 billion and $10.2 billion respectively, with both companies poised to potentially surpass Summit by 2026, highlighting the fierce competition in the biotech sector.
- Axsome's Growth Momentum: Axsome Therapeutics reported a 65.5% revenue increase in 2025, reaching $638.5 million, and is awaiting FDA approval for its Alzheimer's drug AXS-05, which could significantly expand its market reach.
- Madrigal's Sales Surge: Madrigal Pharmaceuticals achieved $958.4 million in sales from its Rezdiffra drug in 2025, a 432% increase from 2024, indicating strong growth potential in the metabolic dysfunction space, with expectations for continued excellent financial performance.
See More
Superstring Capital Acquires Position in Axsome Therapeutics
- New Investment Disclosure: Superstring Capital Management disclosed a new position in Axsome Therapeutics, acquiring 37,433 shares worth $6.84 million in Q4 2025, indicating strong confidence in the company's prospects.
- Asset Allocation Shift: This acquisition represents nearly 4% of Superstring's 13F assets, highlighting Axsome's increasing significance in the portfolio and potentially influencing future investment strategies.
- Strong Company Performance: Axsome Therapeutics boasts a market capitalization of $8.1 billion, with a 27% stock price increase over the past year, significantly outperforming the S&P 500's 19% gain, showcasing its competitive edge in the biopharmaceutical sector.
- Diverse Product Pipeline: Axsome's portfolio includes commercial therapies for depression, migraine, and sleep disorders, which are expected to drive revenue growth, reduce financing risks, and enhance investment appeal.
See More
Investigation into Atkore and Others by Johnson Fistel
- Shareholder Investigation: Johnson Fistel, PLLP is investigating whether executives at Atkore Inc. and others breached their fiduciary duties, allowing shareholders who held shares continuously since specific dates to seek corporate governance reforms.
- Antitrust Allegations: Atkore is accused in a lawsuit of colluding with other PVC pipe manufacturers to engage in price-fixing, which artificially inflated prices and led to a significant decline in pricing once exposed, severely impacting the company's operations.
- Lack of Transparency at Axsome: Axsome Therapeutics faces allegations of failing to disclose critical chemistry and manufacturing issues during the preparation of its New Drug Application, potentially jeopardizing its market prospects and investor confidence.
- CTO's Financial Misrepresentation: CTO Realty Growth is accused of misleading investors about the sustainability of its dividends and using deceptive practices to inflate its financial performance, undermining investor trust in the company's future prospects.
See More
Axsome Acquires Global Rights to TAK-063 from Takeda
- Asset Purchase Agreement: Axsome Therapeutics has signed an asset purchase agreement with Takeda Pharmaceutical to acquire exclusive global rights to TAK-063 (balipodect), further expanding its leading CNS portfolio and demonstrating strategic positioning in neuropsychiatric treatment.
- Clinical Trial Plans: Axsome intends to initiate Phase 3 trial-enabling activities for schizophrenia in 2026, indicating strong confidence in the development of balipodect and aiming to improve treatment outcomes for patients through this novel mechanism.
- Clinical Trial Results: Balipodect has shown positive results in a 164-patient proof-of-concept Phase 2 trial for schizophrenia and has demonstrated a favorable safety and tolerability profile in clinical studies involving over 360 individuals, enhancing its market potential.
- Financial Arrangement: Under the agreement, Axsome obtains worldwide commercial, development, and manufacturing rights to balipodect, while Takeda receives an upfront payment and is eligible for additional payments related to development, regulatory, and commercial milestones, as well as royalties on potential global net sales, ensuring mutual benefit.
See More
FDA Accelerates Biosimilar Drug Development and Approves New Treatments
- Accelerated Biosimilar Development: On March 9, 2026, the FDA recommended streamlining unnecessary clinical pharmacokinetic studies when scientifically justified, aiming to expedite biosimilar drug development and improve medicine affordability, thereby enhancing market competitiveness.
- Alternative to Animal Testing: The FDA released draft guidance on March 18, 2026, to assist drug developers in validating new approach methodologies as alternatives to animal testing, reflecting its commitment to scientific rigor and humane practices, which could reshape drug development standards.
- New Therapy Approval: On March 10, 2026, the FDA approved Wellcovorin as the first treatment for cerebral folate deficiency, a rare neurological condition, marking a significant advancement in neuroscience and potentially offering new hope for patients.
- Gene Therapy Innovation: The FDA approved Rocket Pharma's Kresladi on March 26, 2026, as the first gene therapy for Severe Leukocyte Adhesion Deficiency Type I, showcasing the potential of gene therapy in treating rare diseases and possibly driving stock price increases for related biotech companies.
See More
Summit Therapeutics Faces FDA Review Risk for Ivonescimab
- Regulatory Application Progress: Summit Therapeutics has filed for FDA approval of ivonescimab, which is already approved in China; however, survival data from Western countries has not shown statistical significance, potentially jeopardizing its marketing authorization.
- Market Valuation Changes: Currently, Summit's market cap stands at $12 billion, approximately 48% higher than Axsome and 17% higher than Madrigal, but if the FDA declines ivonescimab, the stock could face a drop of over 20%.
- Competitor Dynamics: Axsome Therapeutics and Madrigal Pharmaceuticals reported revenue growth of 65.5% and 432% in 2025, respectively, indicating strong market potential that could see them surpass Summit in the near future.
- Investor Risk Assessment: While Summit has long-term potential in oncology, its short-term outlook is uncertain, prompting investors to carefully evaluate risks, especially in light of possible negative clinical trial outcomes.
See More
Summit Therapeutics Faces FDA Approval Risk for Ivonescimab
- FDA Approval Crucial: Summit Therapeutics has filed for FDA approval of ivonescimab, which is already approved in China; however, the drug has not shown statistically significant overall survival in Western countries, and a rejection could lead to a significant drop in stock price.
- Intensifying Market Competition: Axsome Therapeutics and Madrigal Pharmaceuticals have market caps of $8.1 billion and $10.2 billion respectively, with both companies poised to potentially surpass Summit by 2026, highlighting the fierce competition in the biotech sector.
- Axsome's Growth Momentum: Axsome Therapeutics reported a 65.5% revenue increase in 2025, reaching $638.5 million, and is awaiting FDA approval for its Alzheimer's drug AXS-05, which could significantly expand its market reach.
- Madrigal's Sales Surge: Madrigal Pharmaceuticals achieved $958.4 million in sales from its Rezdiffra drug in 2025, a 432% increase from 2024, indicating strong growth potential in the metabolic dysfunction space, with expectations for continued excellent financial performance.
See More
Superstring Capital Acquires Position in Axsome Therapeutics
- New Investment Disclosure: Superstring Capital Management disclosed a new position in Axsome Therapeutics, acquiring 37,433 shares worth $6.84 million in Q4 2025, indicating strong confidence in the company's prospects.
- Asset Allocation Shift: This acquisition represents nearly 4% of Superstring's 13F assets, highlighting Axsome's increasing significance in the portfolio and potentially influencing future investment strategies.
- Strong Company Performance: Axsome Therapeutics boasts a market capitalization of $8.1 billion, with a 27% stock price increase over the past year, significantly outperforming the S&P 500's 19% gain, showcasing its competitive edge in the biopharmaceutical sector.
- Diverse Product Pipeline: Axsome's portfolio includes commercial therapies for depression, migraine, and sleep disorders, which are expected to drive revenue growth, reduce financing risks, and enhance investment appeal.
See More
Investigation into Atkore and Others by Johnson Fistel
- Shareholder Investigation: Johnson Fistel, PLLP is investigating whether executives at Atkore Inc. and others breached their fiduciary duties, allowing shareholders who held shares continuously since specific dates to seek corporate governance reforms.
- Antitrust Allegations: Atkore is accused in a lawsuit of colluding with other PVC pipe manufacturers to engage in price-fixing, which artificially inflated prices and led to a significant decline in pricing once exposed, severely impacting the company's operations.
- Lack of Transparency at Axsome: Axsome Therapeutics faces allegations of failing to disclose critical chemistry and manufacturing issues during the preparation of its New Drug Application, potentially jeopardizing its market prospects and investor confidence.
- CTO's Financial Misrepresentation: CTO Realty Growth is accused of misleading investors about the sustainability of its dividends and using deceptive practices to inflate its financial performance, undermining investor trust in the company's future prospects.
See More
